¡@
ĪîP ¤£¥u¬O®J¤ÎÆA¦Zªº¯µ¤è
¡@
¶À³»¥ß DEENG-LIH HUANG, Ph.D.
¬ü°êôÛ¤ñ¨È¤j¾Ç¥Íª«¦³¾÷¤Æ¾Ç³Õ¤h
E-mail: dh459@columbia.edu
(¹q¸£¦r¼Æ²Îp¡G¤¤¤å¦r 1,511¡A^¼Æ¦r 97)
¡@
§A¬O§_ı±o¦p®J¤ÎÆA¦Z
(Cleopatra)
¯ë¨q¦â¥iÀ\¡B¥O¤H««²C¤T¤Øªºº}«G¤k¥Í·U¨Ó·U¦h¤F¡H³o°£¤F¾ã«¬¬ü®e¤j¤Òªº¥\³Ò¥~¡A³¡¤Àì¦]nÂk¥\©ó²{¥N¤ÆùÛ«O¾i«~³£°½¤F·í®É®J¤ÎÆA¦Z¥Î¨Ó«O«ù«C¬K¬üÄRªº¯µ¤è¤§¤@
-- ĪîP (aloe vera)¡C
°£¤F¥Ö½§«O¾i¡A¤£¤Ö¬ã¨sÅã¥ÜĪîP¯à´î»´¿S¶Ë¯kµh¡B«P¶i¶Ë¤f´_ì¡C¨Ò¦p 1995 ¦~¤@¹ï 27
¦ì³¡¤À«p¿N¶Ë¯f¤Hªº¬ã¨s¡AÅã¥Ü´_쪺³t«×ĪîP½¦¤ñ¥«°âªº¤Z¤hªL¯½¥¬§Ö¡A¤Î¦³¸û¤pªºµh¡B¤£µÎªAµ¥°Æ§@¥Î¡A¥§¡´_ì®É¶¡¦U¬ù 11.89 ¤Ñ©M 18.19 ¤Ñ¡Cµv°ò¥Ìªo¥iÄÀ©ñ¤@®ñ¤Æ´á¨Ó«P¶i¶Ë¤f´_ì¡A1997 ¦~¤@¬ã¨sÅã¥Ü¼ÅĪîP«P¶i¶Ë¤f´_쪺³t«×¤ñµv°ò¥ÌªoÁÙ§Ö¡C
1998 ¦~¤GӦѹ«¬ã¨s¡AÅã¥Ü¥~¼Å©Î¤fªAĪîP¥i«P¶i¶Ë¤f´_ì¡A¥~¼Å®ÄªG¤ñ¤fªA²¤¦n¡CĪîP¥i«P¶i¶Ë¤f´_쪺°ò¦ª«½è¿}Ói»E¿}Ãþ (glycoaminoglycans)¡A¬Á§¿»Ä¡B²¸»Ä³n°©¯À B¡B¿}¤ô¸Ñ¨»¨C©M½¦ì³J¥Õªº¼W¥[¨Ó«P¶i¶Ë¤f´_ì¡CÁöµM¿}§¿¯fªº¶Ë¤f¸û¤£©ö´_ì¡A1998 ¦~¤@¬ã¨sÅã¥Ü¥~¼Å©Î¤fªAĪîP¥i«P¶i¿}§¿¯f¦Ñ¹«ªº¶Ë¤f´_ì¡C1990 ¦~¤@¬ã¨s¡A¦b¾ãÁy¥Ö½§¾ã¥¤â³N«á¡AÀ¿ÄªîPªº³o¥bÃäÁyªºÁ`Åé¶Ë¤f²¬Â¡³t«×§Ö¬ù 72 ¤p®É¡C
µM¦Ó¡A¦³¨Ç¤H¥i¯à¤£¾A¥ÎĪîP¡An¤p¤ß¡C¨Ò¦p 1991 ¦~¦³ 41-65 ·³ªº¤T¤k¤@¨k¦b¤Æ¾Ç¥h¥Ö©Î¥Ö½§¾ã¥¤â³N«á¡AÀ¿ÄªîP©Îºû¥L©R E ¦³ÄY«¿U¿N¯ë·Pı¡C¨ä¤¤¤@¤H¦³ÄY«¥Ö½§ª¢¡A»ÝnÀR¯ßª`®gÃþ©T¾J¡C³o¥|¯f¤Hªº¥Ö½§ª¢®ø¥h«ÜºC¡A»Ýn¦Ü¤Ö¤TÓ¤ë®É¶¡¡C 1991 ¦~¤@¬ã¨s¡AÅã¥ÜĪîP·|´î½w帡¥Í²£©Î°ü¬ì帡¤â³Nªº¶Ë¤f´_ì¡A¼Ð·ÇªvÀøªº¶Ë¤f´_ì¤Ñ¼Æ¬° 53
¡Ó 24 ¤Ñ¡A¼Ð·ÇªvÀø¥[ĪîP«h¼W¬° 83 ¡Ó 28 ¤Ñ¡C1996 ¦~ªº¤GÓ¶¥¬q III (Phase III) ªºÀH¾÷Âùª¼¹ï·Ó²Õ±±¨î¬ã¨s¡AÅã¥Ü¼ÅĪîP½¦¨Ã¨S¦³«OÅ@§ïµ½¿ç®g¤Þ°_ªº¥Ö½§ª¢¡C
1995 ¦~¤@¹ï¤Q°¦¯Ã¦èÄõ¥Õ¨ß¦Õ¦·á¶Ëªº¬ã¨s¡AÅã¥ÜĪîP¥i§ïµ½á¶Ë¡AÀ¿ÄªîP²Õ¦³ 24% ²Õ´¦s¬¡¡A¦Ó¹ï·Ó²Õ¥u¦³ 6%¡C
ĪîP¥i§ïµ½¤û¥ÖÅ~¡C1996 ¦~¤@ÀH¾÷Âùª¼¦w¼¢¾¯±±¨î¡A¹ï 36 ¨k 24 ¤k¡B18-50 ·³ (¥§¡ 25.6 ·³)ªº»´«×¨ì¤¤«×´³«¬¤û¥ÖÅ~¯f¤H¬ã¨s¡A¥§¡¿©±w 8.5 ¦~¡A¦U¼Å¦w¼¢¾¯©M 0.5% ĪîPµÑ¨úª«³n»I 16 ¶g¡A¦A°lÂܤ@¦~¡CĪîP²Õ¦³ 83.3% ¯f¤H²¬Â¡¡A¦Ó¦w¼¢¾¯²Õ¥u¦³ 6.6%¡C
1997 ¦~¤@¬ã¨s¡AÅã¥ÜĪîP§t¦³§K¬Ì½Õ¸`¦]¤l¡A¥iÁקKµµ¥~½u±þ¶Ë¤O¸û±jªº UVB »¤µoªº§í¨î¥Ö½§§K¬Ì¥\¯à¡C1998 ¦~ªº¤@¬ã¨s¡AÅã¥Ü¤fªA©Î¥~¼ÅĪîP¥iÀ°§UÀR¯ß¦±±i©Ê¼ìºÅ´_ì¡C
1990 ¦~ªº¤@¬ã¨s¡AÅã¥ÜĪîPªº¤@ºÒ¤ô¤Æ¦Xª« acemannan
¦³§Ü¯f¬r·P¬Vªº§K¬Ì¥\¯à¡C¹j¦~¤@Ãö©ó acemannan ©M·R´þ¯f¯f¬rªº¬ã¨s¡AÅã¥Ü¨C¤Ñ³Ü 0.5-1 ¤½¤ÉªºÄªîP¥Ä¥i¼W±j·R´þ¯fÃÄ AZT ªºÃĮĤΰ§CÃľ¯¶q¡C
Acemannan ªº§K¬Ì¥\¯à©M 1998 ¦~¿Õ¨©º¸Âå¾Ç¼ú¬ã¨s¥DÃD¤@®ñ¤Æ´á (NO) ¦³Ãö¡C1995 ©M 1996 ¦~ªº¤G¬ã¨s¡AÅã¥Ü acemannan ¦U·|¨ë¿EÂûµÊŦ©M¦Ñ¹«¥¨¾½²ÓMªº¤@®ñ¤Æ´á¥Í¦¨¡A¥H½Õ¸`§K¬Ì¥\¯à¤ÏÀ³¡C
CARN 750 ¬O¥i¥Ö¤Uª`®g¡B¿@ÁYªº acemannan¡A1996
¦~¤@¬ã¨sÅã¥Ü¡A CARN 750 ¥i«P¶i¶Ë¤f´_ì¡A¦³§Ü¸~½F¡B¬¡¤Æ¥¨¾½²ÓM¡B¼W¥[²O¤Ú²ÓM©M¥Õ¦å²y¼Æ¶qªº§K¬Ì¥\¯à¡C¦Ñ¹«¹êÅç¡A¥i¨Ï³Q¿ç®g·´Ãaªº¦å²y²ÓM¼W¥[¥Õ¦å²yªº¼W´Þ¡A³o¥iÀ°§U±µ¨ü¤Æ¾Ç©Î¿ç®gÀøªkªº¯f¤H¡A¦ý»Ý§ó¦hªº¬ã¨s¤ä«ù¡C
ªì´ÁÁ{§É¬ã¨sÅã¥Ü¿Æ¶Â¿E¯À (melatonin) ¥i¬¡¤Æ§ÜÀù§K¬Ì¨Ó§ïµ½µLÂ媺Âಾ©Êµw¸~½F¡A¤fªAĪîP¥i¶i¤@¨BÀ°§U¿Æ¶Â¿E¯Àªº¬¡¤Æ§ÜÀù§K¬Ì¥\¯à¡C1998 ¦~¤@¹ï 50 ¦WªÍÀù¡B¸zG¹D¸~½F¡B¨ÅÀù©Î¸£¯«¸g½¦¥À²ÓM½F¯f¤H°µ¤@¦~ªº¬ã¨s¡A26 ¤H¨C±ß¦Y 20 mg ¿Æ¶Â¿E¯À¡A³Ñ¾l 24 ¤H°£¿Æ¶Â¿E¯À¥~¡A¥[¨C¤Ñ¦Y¤G¦¸ 1 mlĪîPª¾¯¡C¯f±¡Ã©wªº¯f¤H¦b¿Æ¶Â¿E¯À²Õ¦³ 7 ¤H (26.9%)¡A¦Ó¥[ĪîP²Õ¦³ 14 ¤H (58.3%)¡C³¡¥÷¦³¤ÏÀ³ªº¯f¤H¦b¿Æ¶Â¿E¯À²ÕµL¤H (0%)¡A¦Ó¥[ĪîP²Õ¦³¤G¤H (8.3%)¡C¤@¦~¦s¬¡²v¦b¿Æ¶Â¿E¯À²Õ¦³ 4 ¤H (15.4%)¡A¦Ó¥[ĪîP²Õ¦³ 9 ¤H (37.5%)¡C
ĪîP§t¦³¤j¶qªºÂmÃĦ¨¤À½µ¨»©ø¥Ì¡A1996
¦~¤@¬ã¨s¡AÅã¥ÜĪîPªº¤@ºØ½µ¨»©ø¥Ì -- ĪîP¤j¶À¥Ì·|§í¨î¤@Ót³d²ÓM¤Àµõ©M DNA
Â_µõªº¨»¨C¡A¦Ó¾ÉP²ÓM¨t DNA ¬ðÅÜ¡C1993
¦~¤@¬ã¨s¡AÅã¥ÜĪîPªº½µ¨»©ø¾J·|¾ÉP¦Ñ¹«ªº¸z¸~½F¡A¦b·í°µÂmÃĮɡA³Q«Øij©M¼W¥[¤HÃþª½¸zÀù¦³Ãö³s¡C
1997 ¦~¤@¬ã¨s¡AÅã¥ÜĪîPªº aloesin ¥i¨ë¿E¤HÃþ¨x²ÓM SK-HEP-1 ¼W¥Í¡C1997 ¦~¤@¦Ñ¹«¬ã¨s¡AÅã¥Ü¹ï¨x²ÓMµL¬r©ÊªºÄªîPµÑ¨úª«¥i´î¤Ö¤@PÀùª«¹ï¨x²ÓM©Ò¤Þ°_ªº DNA ¬ðÅܪº²Ä¤@¨Bµo¥ÍÀW²v 48%¡C1998 ¦~¤@¦Ñ¹«¬ã¨s¡AÅã¥Üºû¥L©R C ©MĪîPµÑ¨úª«³£¥i°§CPÀù¤Æ¾Çª«¹ï¨xªº·lÃa¡FĪîP²Õ¦b¦Y¤@Ó¤ë´NÅã²{¡A¦Ó¦Yºû¥L©R C «hn¤GÓ¤ë¡C
1997 ¦~¤@¬ã¨s¡AÅã¥ÜĪîP½¦§t¦³¦³¬rªº§C¤À¤l¶qª«½è¡CĪîPªººØÃþ¬ù 350 ºØ¡AYn¤fªAn¼f·VÁקK¦³¬r«~ºØ¡C
¡@
(Written on
12/16/1998.)
¡@
©
Copyright 1998-2002 DEENG-LIH HUANG. All rights reserved.
¡@
Posted
on 01/28/2002.
¡@
Disclaimer: ¥»¤åª©Åv¬°§@ªÌ©Ò¦³¡C¤å³¹¤º®e¬O§@ªÌªº³d¥ô¡A¥»ºô¯¸©Î°·±d±ÚªÑ¥÷¦³¤½¥q©M¤å³¹¤º®eµLÃöÁp¨Ã¹ï¤å³¹¤º®e¤£t³d¥ô¡CCopyright of this article belongs to the author. The content of the article is the responsibility of the author. This web site or Health Family Corporation have no correlation with the content of this article and have no responsibility over the content of this article.
¡@
ÁܽZ
¡@
|